Bionor Pharma ASA: BIONOR PHARMA ASA - APPROVED PROSPECTUS AND DETAILS REGARDING SUBSEQUENT OFFERING NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES (Oslo, 8 October 2013) Reference is made to the stock exchange announcements made by Bionor Pharma ASA (the "Company") dated 12 September 2013 and 13 September 2013 regarding (i) a private placement (the "Private Placement") of 19,800,000 new shares in the Company (the "New Shares"), and (ii) the subsequent offering (the "Subsequent Offering") of up to 7,500,000 additional shares in the Company (the "Offer Shares"). The Financial Supervisory Authority of Norway has approved a prospectus (the "Prospectus") for offering and listing of the Offer Shares on Oslo Børs. The subscription period for the Subsequent Offering commences 8 October 2013 and expires at 16:30 hours (CET) on 22 October 2013. The subscription price per Offer Share is NOK 2.75, equal to the subscription price in the Private Placement. The Subsequent Offering will be directed towards existing shareholders as of 12 September 2013, as registered in the VPS on 17 September 2013 (the "Record Date"), who were not allocated shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any filing, registration or similar action, (the "Eligible Shareholders"). Eligible Shareholders have been granted 1 non-transferable Allocation Rights for each 15.628227 existing shares registered as of the Record Date rounded down to the nearest whole subscription right. The Allocation Rights, subject to applicable laws, provide rights to subscribe for and be allocated Offer Shares in the Offering. Over-subscription and subscription without Allocation Rights will be permitted. Allocation rights not used to subscribe for Offer Shares before the end of the subscription period will lapse without compensation to the holder, and consequently be of no value. The Prospectus and subscription form for the Subsequent Offering is available at www.bionorpharma.com or www.seb.no and in hard copy by contacting the subscription office mentioned below or Bionor Pharma directly. An information letter that includes information about where the Prospectus and the subscription form will be available, the number of Allocation rights allocated to the Eligible Shareholder and certain other matters relating to the shareholding will be distributed to all Eligible Shareholders on or about 23 October 2013. The subscription rights can be exercised by duly completing and delivering the subscription form, in accordance with the terms and conditions set out in the Prospectus, to the following subscription office: Skandinaviska Enskilda banken AB (publ) Oslo branch Filipstad Brygge 1 P.O. Box 1843 Vika 0123 Oslo Norway Tel: +47 22 82 70 00 Fax: +47 21 00 89 05 Norwegian residents with a Norwegian personal identification number can subscribe online by accessing one of the web pages above. Any questions or requests for assistance concerning the Subsequent Offering should be directed to the subscription office mentioned above. SEB is acting as sole manager for the Private Placement and the Subsequent Offering. For further information about the Subsequent Offering, reference is made to the Prospectus. For further information, please contact: Synne H Røine, CFO Bionor, +47 99 22 98 92 About Bionor: Bionor Pharma is a leading biotechnology company, searching for breakthrough products for the treatment and prevention of life-threatening viral diseases. The Company is listed on the Oslo Stock Exchange, and is developing vaccines for viral infections. The vaccines are based on a proprietary technology platform developed following more than two decades of research into peptides, and they are designed to safely stimulate the immune system to combat viral diseases. More information about Bionor Pharma is available at www.bionorpharma.com This publication is not for distribution, directly or indirectly, in or into the United States, nor is it an offer for sale of or the solicitation of an offer to purchase securities in the United States. Any securities referred to herein have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an exemption from registration under the U.S. Securities Act. Copies of this publication are not being, and may not be, distributed or sent into the United States. This information is subject of the disclosure requirements acc. to §5-12 (Norwegian Securities Trading Act). ------------------------------------------------------------------------------ This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Bionor Pharma ASA via Thomson Reuters ONE HUG#1734096
Bionor Pharma ASA: BIONOR PHARMA ASA - APPROVED PROSPECTUS AND DETAILS REGARDING SUBSEQUENT OFFERING
Press spacebar to pause and continue. Press esc to stop.